--- title: "Efgartigimod | PepTracker Pro" url: https://peptrackerpro.com/peptides/efgartigimod description: "Efgartigimod (efgartigimod alfa, brand names Vyvgart intravenous and Vyvgart Hytrulo subcutaneous) is a first-in-class antagonist of the neonatal Fc receptor (FcRn) developed by argenx as ARGX-113. It is not a small synthetic peptide but an engineered fragment of the human immunoglobulin G1 (IgG1) antibody - specifically the Fc portion that normally binds FcRn - modified with argenx's ABDEG technology to bind FcRn with much higher affinity than natural IgG at both neutral and acidic pH. FcRn is the salvage receptor that rescues circulating IgG from lysosomal degradation and recycles it back into the blood, giving antibodies their long half-life. By outcompeting endogenous IgG for FcRn, efgartigimod blocks that recycling and drives rapid clearance of IgG - including the pathogenic autoantibodies that cause many autoimmune diseases - typically lowering total IgG by roughly 60-70% within weeks, without reducing IgM, IgA, or albumin. It was the first FcRn blocker ever approved: FDA-approved in December 2021 (Vyvgart IV) for acetylcholine-receptor-antibody-positive generalized myasthenia gravis (gMG) on the strength of the Phase 3 ADAPT trial, followed by a subcutaneous co-formulation with recombinant hyaluronidase (Vyvgart Hytrulo) for gMG in 2023 and for chronic inflammatory demyelinating polyneuropathy (CIDP) in 2024. In May 2026 the FDA expanded the gMG label to all serotypes - including AChR-antibody-negative (seronegative) patients - based on the Phase 3 ADAPT SERON trial, making efgartigimod the first and only therapy approved across every gMG antibody subtype. It is being studied in a broad set of other IgG-driven autoimmune diseases, including primary immune thrombocytopenia, myositis, Sjogren's disease, bullous pemphigoid, and lupus nephritis." lang: en --- Skip to main content **Educational information only.** This site does not provide medical advice. Read full disclaimer (https://peptrackerpro.com/disclaimer) **Research-only content.** This page is for educational purposes and does not constitute medical advice. Read full disclaimer → (https://peptrackerpro.com/research-disclaimer) # Efgartigimod High Evidence Efgartigimod (efgartigimod alfa, brand names Vyvgart intravenous and Vyvgart Hytrulo subcutaneous) is a first-in-class antagonist of the neonatal Fc receptor (FcRn) developed by argenx as ARGX-113. It is not a small synthetic peptide but an engineered fragment of the human immunoglobulin G1 (IgG1) antibody - specifically the Fc portion that normally binds FcRn - modified with argenx's ABDEG technology to bind FcRn with much higher affinity than natural IgG at both neutral and acidic pH. FcRn is the salvage receptor that rescues circulating IgG from lysosomal degradation and recycles it back into the blood, giving antibodies their long half-life. By outcompeting endogenous IgG for FcRn, efgartigimod blocks that recycling and drives rapid clearance of IgG - including the pathogenic autoantibodies that cause many autoimmune diseases - typically lowering total IgG by roughly 60-70% within weeks, without reducing IgM, IgA, or albumin. It was the first FcRn blocker ever approved: FDA-approved in December 2021 (Vyvgart IV) for acetylcholine-receptor-antibody-positive generalized myasthenia gravis (gMG) on the strength of the Phase 3 ADAPT trial, followed by a subcutaneous co-formulation with recombinant hyaluronidase (Vyvgart Hytrulo) for gMG in 2023 and for chronic inflammatory demyelinating polyneuropathy (CIDP) in 2024. In May 2026 the FDA expanded the gMG label to all serotypes - including AChR-antibody-negative (seronegative) patients - based on the Phase 3 ADAPT SERON trial, making efgartigimod the first and only therapy approved across every gMG antibody subtype. It is being studied in a broad set of other IgG-driven autoimmune diseases, including primary immune thrombocytopenia, myositis, Sjogren's disease, bullous pemphigoid, and lupus nephritis. Aliases Efgartigimod +9 more Evidence High Evidence Last Updated 2026-07-23 Reading Time 8 min ## What It Is Efgartigimod is the drug that turned a housekeeping receptor into a therapeutic target. Almost every antibody drug and every natural antibody in the body owes its long life to the neonatal Fc receptor, FcRn - a receptor that grabs IgG inside cells before it can be degraded and ferries it back out into circulation, letting IgG persist for weeks instead of hours. That same recycling machinery keeps pathogenic autoantibodies alive in diseases like myasthenia gravis, where antibodies against the acetylcholine receptor jam signaling at the neuromuscular junction. Efgartigimod exploits the system directly: it is the isolated Fc fragment of a human IgG1 antibody, engineered with argenx's ABDEG (antibodies that enhance IgG degradation) mutations so that it clamps onto FcRn far more tightly than ordinary IgG and, crucially, holds on even at the neutral pH of the cell surface where natural IgG would let go. With FcRn occupied by the drug, circulating IgG can no longer be rescued, so it is routed to the lysosome and destroyed. The effect is a fast, deep, and reversible reduction in total IgG - and therefore in the disease-causing autoantibodies - while leaving IgM, IgA, complement, and albumin untouched, which distinguishes it from broad immunosuppression, plasma exchange, or high-dose IVIg. This selectivity is the whole appeal of the FcRn class. Older approaches to antibody-mediated disease either suppressed the immune system wholesale (steroids, broad immunosuppressants) or physically removed antibodies (plasmapheresis); efgartigimod instead tunes down the IgG pool pharmacologically, on a schedule, and lets it recover between cycles. argenx developed it as ARGX-113 and won the first-ever FcRn-blocker approval in December 2021, when the FDA cleared intravenous Vyvgart for AChR-antibody-positive generalized myasthenia gravis based on ADAPT, a Phase 3 trial in which about 68% of treated patients were MG-ADL responders versus roughly 30% on placebo, with benefits appearing within one to two weeks of a dosing cycle. The company then extended the franchise through formulation and indication: Vyvgart Hytrulo, a subcutaneous co-formulation with Halozyme's recombinant human hyaluronidase PH20 that allows a 30-to-90-second injection instead of an hour-long infusion, was approved for gMG in 2023 and, in June 2024, became the first FcRn blocker approved for CIDP on the basis of the ADHERE study, which used a randomized-withdrawal design to show a sharply lower relapse risk in responders. In April 2025 a prefilled-syringe version enabled at-home self-injection. The most recent milestone came on May 8, 2026, when the FDA broadened the gMG indication to cover all antibody serotypes, including the roughly one in ten gMG patients who are seronegative (no detectable AChR, MuSK, or LRP4 antibodies), after the Phase 3 ADAPT SERON trial showed consistent MG-ADL improvement across MuSK-positive, LRP4-positive, and triple-seronegative patients - making efgartigimod the first and only treatment cleared for every gMG subtype. Because the mechanism is disease-agnostic - it works wherever IgG autoantibodies drive pathology - efgartigimod is in trials across a wide autoimmune landscape, including primary immune thrombocytopenia (the ADVANCE program), idiopathic inflammatory myopathy (myositis), Sjogren's disease, bullous pemphigoid, and lupus nephritis, positioning FcRn blockade as a platform rather than a single-disease drug. Also known as: Efgartigimod, efgartigimod alfa, efgartigimod alfa-fcab, efgartigimod alfa and hyaluronidase-qvfc, ARGX-113, Vyvgart, Vyvgart Hytrulo, FcRn antagonist, neonatal Fc receptor blocker, IgG1 Fc fragment ## Regulatory Status FDA-approved prescription biologic (Rx) Efgartigimod alfa is an FDA-approved prescription biologic marketed by argenx as Vyvgart (intravenous efgartigimod alfa-fcab) and Vyvgart Hytrulo (subcutaneous efgartigimod alfa and hyaluronidase-qvfc, co-formulated with recombinant human hyaluronidase PH20). It is not a dietary supplement, a compounded product, or a research chemical, and it must be prescribed and administered under medical supervision; any 'efgartigimod' or 'ARGX-113' offered by a research-chemical vendor is unverified and should not be used. Approved U.S. indications: generalized myasthenia gravis in adults (initially AChR-antibody-positive in December 2021; expanded to all serotypes including seronegative patients on May 8, 2026) and chronic inflammatory demyelinating polyneuropathy (June 2024, subcutaneous). It is also approved in the EU, Japan, and other markets for gMG. Identifiers: CAS 1821402-21-4; DrugBank DB15270; UNII 961YV2O515; ATC L04AL01. Molecular formula approximately C2310H3554N602O692S14, molar mass ~51.3 kDa. Investigational for primary immune thrombocytopenia, myositis, Sjogren's disease, bullous pemphigoid, and lupus nephritis - uses that are not yet approved. ## Why Researchers Study It Efgartigimod is the proof of concept for an entire drug class - the FcRn antagonists - and the first to reach the market. It matters to researchers because it validated a fundamentally new way to treat antibody-mediated autoimmune disease: instead of suppressing the immune system broadly or filtering antibodies out of the blood mechanically, it pharmacologically lowers the circulating IgG pool by blocking the receptor that recycles it, achieving a fast, deep, selective, and reversible reduction in pathogenic autoantibodies. That selectivity - IgG falls while IgM, IgA, complement, and albumin are spared - makes it a clean tool for asking which diseases are truly driven by IgG autoantibodies, and its rapid onset (benefit within one to two weeks of a cycle) and cyclic dosing make it a model for titratable immunomodulation. Because the mechanism is disease-agnostic, efgartigimod is studied as a platform across myasthenia gravis, CIDP, immune thrombocytopenia, myositis, pemphigoid, and other conditions, and as a benchmark against which newer FcRn blockers (rozanolixizumab, nipocalimab, batoclimab) are measured. It is also a case study in antibody engineering, showing how isolating and mutating a single Fc fragment (the ABDEG modification) can convert a passive structural motif into an active therapeutic. ## Proposed Mechanisms - Engineered fragment of the human IgG1 constant (Fc) region - the exact portion of an antibody that binds the neonatal Fc receptor (FcRn) - rather than a small synthetic peptide, produced as a recombinant biologic - Modified with argenx's ABDEG (antibodies that enhance IgG degradation) technology so it binds FcRn with substantially higher affinity than natural IgG at both acidic (endosomal) and neutral (cell-surface) pH, allowing it to occupy the receptor where ordinary IgG would release - By saturating FcRn, it blocks FcRn-mediated recycling of endogenous IgG; IgG that would normally be rescued from the endosome is instead routed to the lysosome and degraded, lowering total circulating IgG by roughly 60-70% within weeks - Selectively reduces all IgG subclasses - including the pathogenic autoantibodies that drive diseases like myasthenia gravis, CIDP, and immune thrombocytopenia - without lowering IgM, IgA, complement, or albumin, distinguishing it from broad immunosuppression, plasma exchange, and IVIg - In the subcutaneous Vyvgart Hytrulo co-formulation, recombinant human hyaluronidase PH20 (rHuPH20) transiently depolymerizes hyaluronan in the subcutaneous space, allowing a large-volume dose to be delivered as a 30-to-90-second injection instead of an intravenous infusion - Effect is reversible: after a dosing cycle FcRn function and IgG levels recover, enabling cyclic 'reduce and recover' dosing rather than continuous depletion ## Evidence Snapshot High Evidence Low Medium High | Study Type | Model | Outcome | Link | | --- | --- | --- | --- | | Phase 3 (ADAPT, NCT03669588) - randomized, double-blind, placebo-controlled | 167 adults with generalized myasthenia gravis (AChR-antibody-positive and seronegative); intravenous efgartigimod 10 mg/kg in cycles versus placebo | In the AChR-antibody-positive population, 67.7% of efgartigimod-treated patients were MG-ADL responders versus 29.7% on placebo, with clinically meaningful improvement appearing within 1-2 weeks of a cycle. Basis for the first-ever FcRn-blocker approval (Vyvgart, December 2021). Published in Lancet Neurology, 2021 | Source: https://clinicaltrials.gov/study/NCT03669588 | | Phase 2 (ADHERE, NCT04281472) - randomized-withdrawal, placebo-controlled | Adults with chronic inflammatory demyelinating polyneuropathy (CIDP); subcutaneous efgartigimod PH20 (Vyvgart Hytrulo), responders re-randomized to drug or placebo | Efgartigimod produced a markedly lower risk of clinical relapse versus placebo in the randomized-withdrawal period, supporting the June 2024 approval as the first FcRn blocker for CIDP | Source: https://clinicaltrials.gov/study/NCT04281472 | | Phase 3 (ADAPT SERON, NCT06298552) - randomized, double-blind, placebo-controlled | 119 adults with AChR-antibody-negative (seronegative) generalized myasthenia gravis, including MuSK-positive, LRP4-positive, and triple-seronegative cohorts; subcutaneous efgartigimod over a 5-week treatment period | Mean MG-ADL improvement of about 3.35 points at week 4, with consistent MG-ADL and QMG benefit across all seronegative cohorts. Basis for the May 8, 2026 FDA expansion of the gMG label to all serotypes, making efgartigimod the first and only treatment approved for every gMG antibody subtype | Source: https://clinicaltrials.gov/study/NCT06298552 | | Phase 3 (ADVANCE program, incl. SC study NCT04687072) - randomized, placebo-controlled | Adults with primary immune thrombocytopenia (ITP); intravenous and subcutaneous efgartigimod versus placebo, evaluating durable platelet response | Investigational: FcRn blockade lowers anti-platelet IgG and has shown platelet responses in ITP trials; ITP is not yet an approved indication, and this represents an extension of the platform beyond neuromuscular disease | Source: https://clinicaltrials.gov/study/NCT04687072 | ## Commonly Discussed Benefits Immune Modulation: https://peptrackerpro.com/benefits/immune-modulation Neuromuscular Function: https://peptrackerpro.com/benefits/neuromuscular-function Rare Disease Treatment: https://peptrackerpro.com/benefits/rare-disease-treatment Disease Modification: https://peptrackerpro.com/benefits/disease-modification Researching Efgartigimod? Track it, set reminders, and keep notes in the free app. Track in App (https://app.peptrackerpro.com/?add=efgartigimod) ## Safety & Cautions - Efgartigimod is a prescription biologic that must be administered under medical supervision (intravenous Vyvgart or subcutaneous Vyvgart Hytrulo); it is not a supplement or self-sourced research chemical, and any product sold as 'efgartigimod' or 'ARGX-113' outside a pharmacy or clinical trial is unverified and unsafe - By design it lowers total IgG by roughly 60-70%, which can increase susceptibility to infections, particularly respiratory and urinary tract infections; the most common adverse events in trials were infections, headache, and (for the subcutaneous form) injection-site reactions - The long-term consequences of repeated, sustained IgG reduction - including cumulative infection risk and response to vaccines - are still being characterized, and live vaccines are generally avoided during treatment - It selectively reduces IgG but does not address non-IgG disease mechanisms; it is not effective for autoimmune conditions driven by IgM, T cells, or complement independent of IgG, and is not an immunosuppressant in the traditional sense - Approved uses are specific (generalized myasthenia gravis across all serotypes, and CIDP); use in immune thrombocytopenia, myositis, Sjogren's disease, bullous pemphigoid, and lupus nephritis remains investigational and unproven - It is a targeted therapy for antibody-mediated disease and has no established role in performance enhancement, anti-aging, or general wellness - contexts in which the peptide/biologic label is sometimes misapplied ## Comparisons See how Efgartigimod compares to related peptides: Efgartigimod vs Batoclimab: https://peptrackerpro.com/compare/efgartigimod-vs-batoclimab Efgartigimod vs Efzofitimod: https://peptrackerpro.com/compare/efgartigimod-vs-efzofitimod Efgartigimod vs IMVT-1402: https://peptrackerpro.com/compare/efgartigimod-vs-imvt-1402 Efgartigimod vs Larazotide: https://peptrackerpro.com/compare/efgartigimod-vs-larazotide Efgartigimod vs Nipocalimab: https://peptrackerpro.com/compare/efgartigimod-vs-nipocalimab Efgartigimod vs Pegcetacoplan: https://peptrackerpro.com/compare/efgartigimod-vs-pegcetacoplan Efgartigimod vs Rozanolixizumab: https://peptrackerpro.com/compare/efgartigimod-vs-rozanolixizumab Efgartigimod vs Sotatercept: https://peptrackerpro.com/compare/efgartigimod-vs-sotatercept Efgartigimod vs Zilucoplan: https://peptrackerpro.com/compare/efgartigimod-vs-zilucoplan Efgartigimod vs Povetacicept: https://peptrackerpro.com/compare/efgartigimod-vs-povetacicept Efgartigimod vs Felzartamab: https://peptrackerpro.com/compare/efgartigimod-vs-felzartamab Efgartigimod vs Frexalimab: https://peptrackerpro.com/compare/efgartigimod-vs-frexalimab ## Calculator Tools Use our research tools to explore dosing and reconstitution data: Reconstitution Calculator: https://peptrackerpro.com/calculators ## Citations 1. [1] argenx Announces U.S. FDA Approval Expanding VYVGART and VYVGART Hytrulo for Use in All Adult Patients Living with gMG (all serotypes, including seronegative) - argenx, May 2026 PubMed (https://argenx.com/news/2026/press-release-3291372) 2. [2] Efgartigimod Gains FDA Approval as First Treatment for Seronegative Forms of Myasthenia Gravis (ADAPT SERON) - NeurologyLive PubMed (https://www.neurologylive.com/view/efgartigimod-gains-fda-approval-first-treatment-seronegative-forms-of-myasthenia-gravis) 3. [3] FDA Approves Efgartigimod as New Treatment for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - NeurologyLive PubMed (https://www.neurologylive.com/view/fda-approves-efgartigimod-new-treatment-chronic-inflammatory-demyelinating-polyneuropathy) 4. [4] Efgartigimod: A Novel FcRn Antagonist in the Treatment of Autoimmune Diseases (mechanism, ABDEG technology) - The Antibody Society PubMed (https://www.antibodysociety.org/antibody-engineering-therapeutics/efgartigimod-a-novel-fcrn-antagonist-in-the-treatment-of-autoimmune-diseases/) 5. [5] Efgartigimod alfa (identifiers, mechanism of action, indications) - DrugBank DB15270 PubMed (https://go.drugbank.com/drugs/DB15270) 6. [6] Vyvgart (efgartigimod alfa) FDA Approval History - Drugs.com PubMed (https://www.drugs.com/history/vyvgart.html) 7. [7] Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) FDA Approval History - Drugs.com PubMed (https://www.drugs.com/history/vyvgart-hytrulo.html) ### Keep researching in the app - Log Efgartigimod to your private tracker - Set a dosing reminder - Compare it side-by-side with your stack Open PepTracker Pro Free: https://app.peptrackerpro.com/?add=efgartigimod Browse more peptides: https://peptrackerpro.com/peptides ## Related Peptides ### Batoclimab High Evidence Batoclimab (development codes IMVT-1401, RVT-1401, HBM9161, HL161) is an investigational, fully human IgG1 monoclonal antibody that blocks the neonatal Fc receptor (FcRn), developed by Immunovant/Roivant (U.S. and Canada) and Harbour BioMed (Greater China) under license from HanAll Biopharma. It is not a small synthetic peptide but a full-length antibody given as a low-volume subcutaneous injection that patients can self-administer at home. Like the approved FcRn blockers efgartigimod, nipocalimab and rozanolixizumab, it lowers circulating IgG - including pathogenic autoantibodies - but it is best known for two things the others are not: it is the FcRn blocker that generated positive Phase 3 myasthenia gravis data yet was deliberately NOT filed for U.S. approval, and it is the one whose FcRn-mediated albumin recycling blockade produces a distinctive on-target signal of lowered serum albumin and raised LDL cholesterol - the exact liability that drove its makers to a re-engineered successor, IMVT-1402. View Details: https://peptrackerpro.com/peptides/batoclimab \+ Compare: https://peptrackerpro.com/compare?select=batoclimab Track in App: https://app.peptrackerpro.com/?add=batoclimab ### Efzofitimod Medium Evidence A first-in-class, intravenous immunomodulatory fusion peptide derived from histidyl-tRNA synthetase that selectively binds neuropilin-2 (NRP2) to dampen inflammation in the lung; in Phase 3 development for pulmonary sarcoidosis, an interstitial lung disease. Inflammation: https://peptrackerpro.com/benefits/inflammation Immune Support: https://peptrackerpro.com/benefits/immune-support View Details: https://peptrackerpro.com/peptides/efzofitimod \+ Compare: https://peptrackerpro.com/compare?select=efzofitimod Track in App: https://app.peptrackerpro.com/?add=efzofitimod ### IMVT-1402 Medium Evidence IMVT-1402 (international nonproprietary name imeroprubart; originally HL161ANS) is Immunovant/Roivant's investigational, next-generation, fully human IgG1 monoclonal antibody that blocks the neonatal Fc receptor (FcRn). It is a re-engineered successor to batoclimab, built to keep batoclimab's deep IgG-lowering while removing that molecule's defining liability: because FcRn recycles serum albumin as well as IgG, first-generation FcRn blockers reproducibly lowered albumin and raised LDL cholesterol, and IMVT-1402 was specifically designed to spare albumin and lipids. Like the approved FcRn blockers efgartigimod, nipocalimab and rozanolixizumab it lowers circulating IgG - including pathogenic autoantibodies - but it is distinguished by two things: a low-volume subcutaneous autoinjector for at-home self-administration, and Phase 1 data showing 60-80% IgG reduction with no albumin drop and no LDL rise. It is now Immunovant's lead pipeline asset, advancing across roughly six autoimmune indications with potentially registrational Graves' disease and myasthenia gravis readouts expected in 2027. View Details: https://peptrackerpro.com/peptides/imvt-1402 \+ Compare: https://peptrackerpro.com/compare?select=imvt-1402 Track in App: https://app.peptrackerpro.com/?add=imvt-1402 ### Larazotide Medium Evidence A synthetic peptide tight junction regulator in clinical trials for celiac disease, designed to prevent intestinal permeability caused by gluten exposure. Gut Health: https://peptrackerpro.com/benefits/gut-health Inflammation: https://peptrackerpro.com/benefits/inflammation Immune Support: https://peptrackerpro.com/benefits/immune-support View Details: https://peptrackerpro.com/peptides/larazotide \+ Compare: https://peptrackerpro.com/compare?select=larazotide Track in App: https://app.peptrackerpro.com/?add=larazotide ### Nipocalimab High Evidence Nipocalimab (brand name Imaavy, development code M281) is a fully human, aglycosylated, 'effectorless' IgG1 monoclonal antibody that blocks the neonatal Fc receptor (FcRn), developed by Johnson & Johnson (Janssen). Like efgartigimod it lowers circulating immunoglobulin G (IgG) - including the pathogenic autoantibodies that drive many autoimmune diseases - by occupying FcRn and preventing it from recycling IgG back into the blood, so unrescued IgG is routed to the lysosome and degraded, typically cutting total IgG by roughly 65-75% while sparing IgM, IgA, complement, and albumin. Unlike efgartigimod's engineered Fc fragment, nipocalimab is a full-length monoclonal antibody engineered to be aglycosylated and effectorless (it does not trigger ADCC or complement-dependent cytotoxicity), and it is dosed as a maintenance intravenous infusion for continuous IgG suppression rather than in short cycles. The FDA approved Imaavy on April 30, 2025 for generalized myasthenia gravis (gMG) in anti-AChR-antibody-positive and anti-MuSK-antibody-positive patients aged 12 and older - making it the first FcRn blocker approved for adolescents and the first to explicitly cover MuSK-positive disease - on the strength of the Phase 3 Vivacity-MG3 trial. It has since generated positive data across a striking breadth of IgG-mediated conditions: Sjogren's disease (Phase 2 DAHLIAS), rheumatoid arthritis, warm autoimmune hemolytic anemia (wAIHA), and - uniquely among FcRn blockers - maternal-fetal alloimmune disease, where it is being developed to treat hemolytic disease of the fetus and newborn (HDFN) by crossing the placenta to protect the fetus. In April 2026 the FDA granted Priority Review to nipocalimab for wAIHA, positioning it as a potential first approved therapy for that condition. View Details: https://peptrackerpro.com/peptides/nipocalimab \+ Compare: https://peptrackerpro.com/compare?select=nipocalimab Track in App: https://app.peptrackerpro.com/?add=nipocalimab ### Pegcetacoplan High Evidence A PEGylated cyclic-peptide inhibitor of complement component 3 (C3) built from two compstatin (Cp05) peptide domains bridged by a 40-kDa PEG chain; marketed as Empaveli/Aspaveli (subcutaneous, for paroxysmal nocturnal hemoglobinuria and, since July 2025, C3 glomerulopathy and primary IC-MPGN) and Syfovre (intravitreal, for geographic atrophy in age-related macular degeneration). It is one of the few complement-targeting therapeutic peptides to reach the market. Immune Support: https://peptrackerpro.com/benefits/immune-support Inflammation: https://peptrackerpro.com/benefits/inflammation View Details: https://peptrackerpro.com/peptides/pegcetacoplan \+ Compare: https://peptrackerpro.com/compare?select=pegcetacoplan Track in App: https://app.peptrackerpro.com/?add=pegcetacoplan ### Rozanolixizumab High Evidence Rozanolixizumab (brand name Rystiggo, development code UCB7665) is a humanized IgG4 monoclonal antibody that blocks the neonatal Fc receptor (FcRn), developed by UCB. Like efgartigimod and nipocalimab it lowers circulating immunoglobulin G (IgG) - including the pathogenic autoantibodies that drive many autoimmune diseases - by binding FcRn and preventing it from recycling IgG back into the blood, so unrescued IgG is routed to the lysosome and degraded, typically cutting total IgG by roughly 70-80% while sparing IgM, IgA, complement, and albumin. Unlike efgartigimod's engineered Fc fragment, rozanolixizumab is a full-length humanized antibody, and unlike nipocalimab's intravenous infusion it is given as a rapid subcutaneous infusion (including via an on-body delivery device), typically in weekly cycles that are repeated based on clinical response rather than continuously. The FDA approved Rystiggo on June 27, 2023 for generalized myasthenia gravis (gMG) in adults who are anti-acetylcholine-receptor (AChR) antibody-positive or anti-muscle-specific-tyrosine-kinase (MuSK) antibody-positive - making it the first therapy ever approved to treat both of those gMG subtypes - on the strength of the Phase 3 MycarinG trial. It has since been studied across other IgG-mediated diseases, including chronic inflammatory demyelinating polyneuropathy (CIDP), where it did not show meaningful benefit and was not advanced to Phase 3, and myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD), primary immune thrombocytopenia (ITP), and other autoantibody conditions where development continues. The European Medicines Agency approved rozanolixizumab in January 2024 and the UK MHRA in March 2024. View Details: https://peptrackerpro.com/peptides/rozanolixizumab \+ Compare: https://peptrackerpro.com/compare?select=rozanolixizumab Track in App: https://app.peptrackerpro.com/?add=rozanolixizumab ### Sotatercept High Evidence Sotatercept (Winrevair, sotatercept-csrk) is Merck's first-in-class activin signaling inhibitor - a recombinant ActRIIA-Fc fusion protein that acts as a ligand trap for activin A, activin B, GDF-8 (myostatin) and GDF-11. It is FDA-approved for adults with pulmonary arterial hypertension (PAH), where it improved 6-minute walk distance by 40.8 meters in the Phase 3 STELLAR trial and, in the Phase 3 ZENITH trial in high-risk patients, cut the composite risk of death, lung transplantation and PAH hospitalization by 76%. An expanded U.S. label reflecting ZENITH was approved on October 27, 2025. Cardiovascular: https://peptrackerpro.com/benefits/cardiovascular Energy: https://peptrackerpro.com/benefits/energy Rare Disease Treatment: https://peptrackerpro.com/benefits/rare-disease-treatment Disease Modification: https://peptrackerpro.com/benefits/disease-modification View Details: https://peptrackerpro.com/peptides/sotatercept \+ Compare: https://peptrackerpro.com/compare?select=sotatercept Track in App: https://app.peptrackerpro.com/?add=sotatercept ### Zilucoplan High Evidence A self-administered, once-daily subcutaneous macrocyclic peptide that inhibits complement component 5 (C5), FDA- and EMA-approved for anti-AChR-positive generalized myasthenia gravis. Immune Modulation: https://peptrackerpro.com/benefits/immune-modulation Neuromuscular Function: https://peptrackerpro.com/benefits/neuromuscular-function View Details: https://peptrackerpro.com/peptides/zilucoplan \+ Compare: https://peptrackerpro.com/compare?select=zilucoplan Track in App: https://app.peptrackerpro.com/?add=zilucoplan ### Povetacicept High Evidence Povetacicept (development code ALPN-303) is an investigational, once-monthly, subcutaneously injected recombinant fusion protein that simultaneously blocks two B-cell survival signals - BAFF (B-cell activating factor) and APRIL (a proliferation-inducing ligand). It is built from an engineered ('variant') form of the natural TACI receptor's extracellular domain fused to an antibody (IgG) Fc region, so it acts as a high-affinity decoy that soaks up both BAFF and APRIL before they can reach their receptors on B cells and plasma cells. Because BAFF and APRIL drive the maturation and antibody production of the immune cells behind many autoantibody- and immune-complex-mediated diseases, povetacicept is being developed for B-cell-driven autoimmune conditions - most prominently IgA nephropathy (IgAN), where APRIL fuels the production of the galactose-deficient IgA1 that damages the kidney. Originated by Alpine Immune Sciences (acquired by Vertex Pharmaceuticals in 2024), povetacicept has received FDA Breakthrough Therapy Designation for IgAN; in March 2026 the Phase 3 RAINIER trial reported a positive prespecified Week 36 interim analysis (a ~52% reduction in urine protein-to-creatinine ratio from baseline and a ~50% reduction versus placebo), and in June 2026 the FDA accepted a Biologics License Application for accelerated approval with a target action date of November 30, 2026. Povetacicept is an experimental biologic given only in clinical trials; it is not a supplement, nootropic, or research chemical. renal: https://peptrackerpro.com/benefits/renal autoimmune: https://peptrackerpro.com/benefits/autoimmune Disease Modification: https://peptrackerpro.com/benefits/disease-modification B-cell-modulation: https://peptrackerpro.com/benefits/B-cell-modulation View Details: https://peptrackerpro.com/peptides/povetacicept \+ Compare: https://peptrackerpro.com/compare?select=povetacicept Track in App: https://app.peptrackerpro.com/?add=povetacicept ### Felzartamab Medium Evidence Felzartamab (development codes MOR202/MOR03087, and TJ202 in Greater China) is an investigational fully human IgG1 monoclonal antibody that targets CD38, a protein carried at high density on the antibody-producing plasma cells and plasmablasts of the immune system. Rather than blocking a single circulating antibody or downstream mediator, felzartamab depletes the very cells that manufacture pathogenic (disease-causing) antibodies, with the logic that shutting down the factory stops the harmful antibodies at their source. CD38 antibodies are an established drug class in cancer (daratumumab and isatuximab are approved for multiple myeloma), and felzartamab is being repurposed to switch off the autoantibody-driven immune attack behind several serious kidney diseases. It is given as an intravenous infusion in defined treatment courses (for example, a roughly five- to nine-dose regimen) rather than indefinitely. Felzartamab has become one of the most closely watched agents in nephrology because it is advancing through three separate Phase 3 programs in rare, antibody-mediated kidney diseases: IgA nephropathy (IgAN), primary membranous nephropathy (PMN), and late antibody-mediated rejection (AMR) of a transplanted kidney. It originated at MorphoSys AG, was licensed to Human Immunology Biosciences (HI-Bio), which Biogen acquired in 2024, and Biogen consolidated the Greater China rights from TJ Biopharma in 2026. It holds FDA Breakthrough Therapy designation in primary membranous nephropathy. Felzartamab is an investigational prescription biologic administered under medical supervision; it is not approved for kidney disease, and it is not a supplement, nootropic or research chemical. View Details: https://peptrackerpro.com/peptides/felzartamab \+ Compare: https://peptrackerpro.com/compare?select=felzartamab Track in App: https://app.peptrackerpro.com/?add=felzartamab ### Frexalimab High Evidence Frexalimab (SAR441344) is an investigational second-generation, fully human monoclonal antibody from Sanofi that blocks CD40 ligand (CD40L, also called CD154), a costimulatory 'second signal' that helps activate B cells, T cells and antigen-presenting cells and drives adaptive autoimmunity. Rather than depleting immune cells, frexalimab interrupts the CD40-CD40L checkpoint upstream - a mechanism related to but distinct from the OX40-OX40L blockade of amlitelimab. Its lead indication is relapsing multiple sclerosis (RMS), with a second program in nonrelapsing secondary progressive MS (nrSPMS). In the Phase 2 relapsing-MS trial (NCT04879628, published in the New England Journal of Medicine in 2024), frexalimab cut the number of new gadolinium-enhancing brain lesions at week 12 by 89% (higher-dose IV arm) and 79% (lower-dose subcutaneous arm) versus placebo, and open-label extensions out to two and three years show that disease control and reductions in neurofilament light have been sustained. Crucially, frexalimab is engineered so its Fc region does not activate platelets, which is designed to avoid the thromboembolic complications that halted first-generation anti-CD40L antibodies decades ago. It is now in the Phase 3 FREXALT (relapsing MS, versus teriflunomide) and FREVIVA (nrSPMS, versus placebo) trials, with additional Phase 2 programs in type 1 diabetes (FABULINUS) and systemic lupus erythematosus; a Sjogren's syndrome study was discontinued in 2024 after it fell short on efficacy. Frexalimab is investigational and not approved by any regulator. Immune Modulation: https://peptrackerpro.com/benefits/immune-modulation Inflammation: https://peptrackerpro.com/benefits/inflammation autoimmune: https://peptrackerpro.com/benefits/autoimmune Disease Modification: https://peptrackerpro.com/benefits/disease-modification View Details: https://peptrackerpro.com/peptides/frexalimab \+ Compare: https://peptrackerpro.com/compare?select=frexalimab Track in App: https://app.peptrackerpro.com/?add=frexalimab ## Structured data ```json [ { "@context": "https://schema.org", "@type": "Organization", "name": "PepTracker Pro", "url": "https://peptrackerpro.com", "logo": "https://peptrackerpro.com/favicon.png", "description": "Evidence-based educational resource dedicated to improving peptide research literacy.", "contactPoint": { "@type": "ContactPoint", "email": "hello@peptrackerpro.com", "contactType": "customer support" }, "sameAs": [] }, { "@context": "https://schema.org", "@type": "MedicalWebPage", "name": "Efgartigimod", "description": "Efgartigimod (efgartigimod alfa, brand names Vyvgart intravenous and Vyvgart Hytrulo subcutaneous) is a first-in-class antagonist of the neonatal Fc receptor (FcRn) developed by argenx as ARGX-113. It is not a small synthetic peptide but an engineered fragment of the human immunoglobulin G1 (IgG1) antibody - specifically the Fc portion that normally binds FcRn - modified with argenx's ABDEG technology to bind FcRn with much higher affinity than natural IgG at both neutral and acidic pH. FcRn is the salvage receptor that rescues circulating IgG from lysosomal degradation and recycles it back into the blood, giving antibodies their long half-life. By outcompeting endogenous IgG for FcRn, efgartigimod blocks that recycling and drives rapid clearance of IgG - including the pathogenic autoantibodies that cause many autoimmune diseases - typically lowering total IgG by roughly 60-70% within weeks, without reducing IgM, IgA, or albumin. It was the first FcRn blocker ever approved: FDA-approved in December 2021 (Vyvgart IV) for acetylcholine-receptor-antibody-positive generalized myasthenia gravis (gMG) on the strength of the Phase 3 ADAPT trial, followed by a subcutaneous co-formulation with recombinant hyaluronidase (Vyvgart Hytrulo) for gMG in 2023 and for chronic inflammatory demyelinating polyneuropathy (CIDP) in 2024. In May 2026 the FDA expanded the gMG label to all serotypes - including AChR-antibody-negative (seronegative) patients - based on the Phase 3 ADAPT SERON trial, making efgartigimod the first and only therapy approved across every gMG antibody subtype. It is being studied in a broad set of other IgG-driven autoimmune diseases, including primary immune thrombocytopenia, myositis, Sjogren's disease, bullous pemphigoid, and lupus nephritis.", "url": "https://peptrackerpro.com/peptides/efgartigimod", "lastReviewed": "2026-07-23", "reviewedBy": { "@type": "Organization", "name": "PepTracker Pro Research Team", "url": "https://peptrackerpro.com" }, "isPartOf": { "@type": "WebSite", "name": "PepTracker Pro", "url": "https://peptrackerpro.com" } }, { "@context": "https://schema.org", "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "Home", "item": "https://peptrackerpro.com" }, { "@type": "ListItem", "position": 2, "name": "Peptides", "item": "https://peptrackerpro.com/peptides" }, { "@type": "ListItem", "position": 3, "name": "Efgartigimod", "item": "https://peptrackerpro.com/peptides/efgartigimod" } ] }, { "@context": "https://schema.org", "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Patients and neurologists managing generalized myasthenia gravis - including seronegative patients newly covered by the 2026 label expansion - who want to understand how an FcRn blocker differs from steroids, broad immunosuppressants, IVIg, plasma exchange, or complement inhibitors like zilucoplan?", "acceptedAnswer": { "@type": "Answer", "text": "Efgartigimod is a research peptide studied in preclinical models. Efgartigimod (efgartigimod alfa, brand names Vyvgart intravenous and Vyvgart Hytrulo subcutaneous) is a first-in-class antagonist of the neonatal Fc receptor (FcRn) developed by argenx as ARGX-113. It is not a small synthetic peptide but an engineered fragment of the human immunoglobulin G1 (IgG1) antibody - specifically the Fc portion that normally binds FcRn - modified with argenx's ABDEG technology to bind FcRn with much higher affinity than natural IgG at both neutral and acidic pH. FcRn is the salvage receptor that rescues circulating IgG from lysosomal degradation and recycles it back into the blood, giving antibodies their long half-life. By outcompeting endogenous IgG for FcRn, efgartigimod blocks that recycling and drives rapid clearance of IgG - including the pathogenic autoantibodies that cause many autoimmune diseases - typically lowering total IgG by roughly 60-70% within weeks, without reducing IgM, IgA, or albumin. It was the first FcRn blocker ever approved: FDA-approved in December 2021 (Vyvgart IV) for acetylcholine-receptor-antibody-positive generalized myasthenia gravis (gMG) on the strength of the Phase 3 ADAPT trial, followed by a subcutaneous co-formulation with recombinant hyaluronidase (Vyvgart Hytrulo) for gMG in 2023 and for chronic inflammatory demyelinating polyneuropathy (CIDP) in 2024. In May 2026 the FDA expanded the gMG label to all serotypes - including AChR-antibody-negative (seronegative) patients - based on the Phase 3 ADAPT SERON trial, making efgartigimod the first and only therapy approved across every gMG antibody subtype. It is being studied in a broad set of other IgG-driven autoimmune diseases, including primary immune thrombocytopenia, myositis, Sjogren's disease, bullous pemphigoid, and lupus nephritis." } }, { "@type": "Question", "name": "People with CIDP and their clinicians evaluating subcutaneous efgartigimod (Vyvgart Hytrulo) as an at-home, self-injected option versus IVIg?", "acceptedAnswer": { "@type": "Answer", "text": "Efgartigimod is a research peptide studied in preclinical models. Efgartigimod (efgartigimod alfa, brand names Vyvgart intravenous and Vyvgart Hytrulo subcutaneous) is a first-in-class antagonist of the neonatal Fc receptor (FcRn) developed by argenx as ARGX-113. It is not a small synthetic peptide but an engineered fragment of the human immunoglobulin G1 (IgG1) antibody - specifically the Fc portion that normally binds FcRn - modified with argenx's ABDEG technology to bind FcRn with much higher affinity than natural IgG at both neutral and acidic pH. FcRn is the salvage receptor that rescues circulating IgG from lysosomal degradation and recycles it back into the blood, giving antibodies their long half-life. By outcompeting endogenous IgG for FcRn, efgartigimod blocks that recycling and drives rapid clearance of IgG - including the pathogenic autoantibodies that cause many autoimmune diseases - typically lowering total IgG by roughly 60-70% within weeks, without reducing IgM, IgA, or albumin. It was the first FcRn blocker ever approved: FDA-approved in December 2021 (Vyvgart IV) for acetylcholine-receptor-antibody-positive generalized myasthenia gravis (gMG) on the strength of the Phase 3 ADAPT trial, followed by a subcutaneous co-formulation with recombinant hyaluronidase (Vyvgart Hytrulo) for gMG in 2023 and for chronic inflammatory demyelinating polyneuropathy (CIDP) in 2024. In May 2026 the FDA expanded the gMG label to all serotypes - including AChR-antibody-negative (seronegative) patients - based on the Phase 3 ADAPT SERON trial, making efgartigimod the first and only therapy approved across every gMG antibody subtype. It is being studied in a broad set of other IgG-driven autoimmune diseases, including primary immune thrombocytopenia, myositis, Sjogren's disease, bullous pemphigoid, and lupus nephritis." } }, { "@type": "Question", "name": "Researchers and students studying FcRn biology, IgG recycling, and antibody engineering, for whom efgartigimod's ABDEG-modified Fc fragment is the canonical example of the class?", "acceptedAnswer": { "@type": "Answer", "text": "Efgartigimod is a research peptide studied in preclinical models. Efgartigimod (efgartigimod alfa, brand names Vyvgart intravenous and Vyvgart Hytrulo subcutaneous) is a first-in-class antagonist of the neonatal Fc receptor (FcRn) developed by argenx as ARGX-113. It is not a small synthetic peptide but an engineered fragment of the human immunoglobulin G1 (IgG1) antibody - specifically the Fc portion that normally binds FcRn - modified with argenx's ABDEG technology to bind FcRn with much higher affinity than natural IgG at both neutral and acidic pH. FcRn is the salvage receptor that rescues circulating IgG from lysosomal degradation and recycles it back into the blood, giving antibodies their long half-life. By outcompeting endogenous IgG for FcRn, efgartigimod blocks that recycling and drives rapid clearance of IgG - including the pathogenic autoantibodies that cause many autoimmune diseases - typically lowering total IgG by roughly 60-70% within weeks, without reducing IgM, IgA, or albumin. It was the first FcRn blocker ever approved: FDA-approved in December 2021 (Vyvgart IV) for acetylcholine-receptor-antibody-positive generalized myasthenia gravis (gMG) on the strength of the Phase 3 ADAPT trial, followed by a subcutaneous co-formulation with recombinant hyaluronidase (Vyvgart Hytrulo) for gMG in 2023 and for chronic inflammatory demyelinating polyneuropathy (CIDP) in 2024. In May 2026 the FDA expanded the gMG label to all serotypes - including AChR-antibody-negative (seronegative) patients - based on the Phase 3 ADAPT SERON trial, making efgartigimod the first and only therapy approved across every gMG antibody subtype. It is being studied in a broad set of other IgG-driven autoimmune diseases, including primary immune thrombocytopenia, myositis, Sjogren's disease, bullous pemphigoid, and lupus nephritis." } }, { "@type": "Question", "name": "Immunologists and drug developers comparing the FcRn antagonists - efgartigimod, rozanolixizumab, nipocalimab, and batoclimab - and tracking which autoimmune indications the mechanism can reach?", "acceptedAnswer": { "@type": "Answer", "text": "Efgartigimod is a research peptide studied in preclinical models. Efgartigimod (efgartigimod alfa, brand names Vyvgart intravenous and Vyvgart Hytrulo subcutaneous) is a first-in-class antagonist of the neonatal Fc receptor (FcRn) developed by argenx as ARGX-113. It is not a small synthetic peptide but an engineered fragment of the human immunoglobulin G1 (IgG1) antibody - specifically the Fc portion that normally binds FcRn - modified with argenx's ABDEG technology to bind FcRn with much higher affinity than natural IgG at both neutral and acidic pH. FcRn is the salvage receptor that rescues circulating IgG from lysosomal degradation and recycles it back into the blood, giving antibodies their long half-life. By outcompeting endogenous IgG for FcRn, efgartigimod blocks that recycling and drives rapid clearance of IgG - including the pathogenic autoantibodies that cause many autoimmune diseases - typically lowering total IgG by roughly 60-70% within weeks, without reducing IgM, IgA, or albumin. It was the first FcRn blocker ever approved: FDA-approved in December 2021 (Vyvgart IV) for acetylcholine-receptor-antibody-positive generalized myasthenia gravis (gMG) on the strength of the Phase 3 ADAPT trial, followed by a subcutaneous co-formulation with recombinant hyaluronidase (Vyvgart Hytrulo) for gMG in 2023 and for chronic inflammatory demyelinating polyneuropathy (CIDP) in 2024. In May 2026 the FDA expanded the gMG label to all serotypes - including AChR-antibody-negative (seronegative) patients - based on the Phase 3 ADAPT SERON trial, making efgartigimod the first and only therapy approved across every gMG antibody subtype. It is being studied in a broad set of other IgG-driven autoimmune diseases, including primary immune thrombocytopenia, myositis, Sjogren's disease, bullous pemphigoid, and lupus nephritis." } }, { "@type": "Question", "name": "Investors and industry analysts following argenx and the expansion of FcRn blockade from myasthenia gravis into ITP, myositis, and other IgG-driven diseases?", "acceptedAnswer": { "@type": "Answer", "text": "Efgartigimod is a research peptide studied in preclinical models. Efgartigimod (efgartigimod alfa, brand names Vyvgart intravenous and Vyvgart Hytrulo subcutaneous) is a first-in-class antagonist of the neonatal Fc receptor (FcRn) developed by argenx as ARGX-113. It is not a small synthetic peptide but an engineered fragment of the human immunoglobulin G1 (IgG1) antibody - specifically the Fc portion that normally binds FcRn - modified with argenx's ABDEG technology to bind FcRn with much higher affinity than natural IgG at both neutral and acidic pH. FcRn is the salvage receptor that rescues circulating IgG from lysosomal degradation and recycles it back into the blood, giving antibodies their long half-life. By outcompeting endogenous IgG for FcRn, efgartigimod blocks that recycling and drives rapid clearance of IgG - including the pathogenic autoantibodies that cause many autoimmune diseases - typically lowering total IgG by roughly 60-70% within weeks, without reducing IgM, IgA, or albumin. It was the first FcRn blocker ever approved: FDA-approved in December 2021 (Vyvgart IV) for acetylcholine-receptor-antibody-positive generalized myasthenia gravis (gMG) on the strength of the Phase 3 ADAPT trial, followed by a subcutaneous co-formulation with recombinant hyaluronidase (Vyvgart Hytrulo) for gMG in 2023 and for chronic inflammatory demyelinating polyneuropathy (CIDP) in 2024. In May 2026 the FDA expanded the gMG label to all serotypes - including AChR-antibody-negative (seronegative) patients - based on the Phase 3 ADAPT SERON trial, making efgartigimod the first and only therapy approved across every gMG antibody subtype. It is being studied in a broad set of other IgG-driven autoimmune diseases, including primary immune thrombocytopenia, myositis, Sjogren's disease, bullous pemphigoid, and lupus nephritis." } }, { "@type": "Question", "name": "Anyone who has encountered 'efgartigimod' or 'ARGX-113' described as a peptide and needs to understand that it is an approved antibody-fragment biologic, prescribed and supervised, not a research-chemical peptide?", "acceptedAnswer": { "@type": "Answer", "text": "Efgartigimod is a research peptide studied in preclinical models. Efgartigimod (efgartigimod alfa, brand names Vyvgart intravenous and Vyvgart Hytrulo subcutaneous) is a first-in-class antagonist of the neonatal Fc receptor (FcRn) developed by argenx as ARGX-113. It is not a small synthetic peptide but an engineered fragment of the human immunoglobulin G1 (IgG1) antibody - specifically the Fc portion that normally binds FcRn - modified with argenx's ABDEG technology to bind FcRn with much higher affinity than natural IgG at both neutral and acidic pH. FcRn is the salvage receptor that rescues circulating IgG from lysosomal degradation and recycles it back into the blood, giving antibodies their long half-life. By outcompeting endogenous IgG for FcRn, efgartigimod blocks that recycling and drives rapid clearance of IgG - including the pathogenic autoantibodies that cause many autoimmune diseases - typically lowering total IgG by roughly 60-70% within weeks, without reducing IgM, IgA, or albumin. It was the first FcRn blocker ever approved: FDA-approved in December 2021 (Vyvgart IV) for acetylcholine-receptor-antibody-positive generalized myasthenia gravis (gMG) on the strength of the Phase 3 ADAPT trial, followed by a subcutaneous co-formulation with recombinant hyaluronidase (Vyvgart Hytrulo) for gMG in 2023 and for chronic inflammatory demyelinating polyneuropathy (CIDP) in 2024. In May 2026 the FDA expanded the gMG label to all serotypes - including AChR-antibody-negative (seronegative) patients - based on the Phase 3 ADAPT SERON trial, making efgartigimod the first and only therapy approved across every gMG antibody subtype. It is being studied in a broad set of other IgG-driven autoimmune diseases, including primary immune thrombocytopenia, myositis, Sjogren's disease, bullous pemphigoid, and lupus nephritis." } } ] } ] ```